RT Journal Article
SR Electronic
T1 Behavioral effects of multiple-dose oxytocin treatment in autism: A randomized, placebo-controlled trial with long-term follow-up
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19012112
DO 10.1101/19012112
A1 Sylvie Bernaerts
A1 Bart Boets
A1 Guy Bosmans
A1 Jean Steyaert
A1 Kaat Alaerts
YR 2019
UL http://medrxiv.org/content/early/2019/11/18/19012112.abstract
AB Background Intranasal administration of the ‘prosocial’ neuropeptide oxytocin is increasingly explored as a potential treatment for targeting the core characteristics of autism spectrum disorder (ASD). However, long-term follow-up studies, evaluating the possibility of long-lasting retention effects are currently lacking.Methods Using a double-blind, randomized, placebo-controlled, parallel design, this pilot clinical trial explored the possibility of long-lasting behavioral effects of four weeks of intranasal oxytocin treatment (24 International Units once daily in the morning) in 40 adult men with ASD. To do so, self-report and informant-based questionnaires assessing core autism symptoms and characterizations of attachment were administered at baseline, immediately after four weeks of treatment (approximately 24 hours after the last nasal spray administration), and at two follow-up sessions, four weeks and one year post-treatment.Results No treatment-specific effects were identified in the primary outcome assessing social symptoms (Social responsiveness scale, self- and informant-rated). In particular, with respect to self-reported social responsiveness, improvements were evident both in the oxytocin and in the placebo group, yielding no significant between-group difference (p= .37). Also informant-rated improvements in social responsiveness were not significantly larger in the oxytocin, compared to the placebo group (between-group difference: p= .19).Among the secondary outcome measures, treatment-specific improvements were identified in the Repetitive Behavior Scale and State Adult Attachment Measure, indicating reductions in self-reported repetitive behaviours (p= .04) and reduced feelings of avoidance towards others (p= .03) in the oxytocin group compared to the placebo group, up to one month and even one year post-treatment. Treatment-specific effects were also revealed in screenings of mood states (Profile of Mood States), indicating higher reports of ‘vigor’ (feeling energetic, active, lively) in the oxytocin, compared to the placebo group (p= .03).Conclusions While no treatment-specific improvements were evident in terms of core social symptoms, the current observations of long-term beneficial effects on repetitive behaviors and feelings of avoidance are promising and suggestive of a therapeutic potential of oxytocin treatment for ASD. However, given the exploratory nature of this pilot study, future studies are warranted to evaluate the long-term effects of OT administration further.Trial Registration The trial was registered with the European Clinical Trial Registry (Eudract 2014-000586-45) on January 22, 2014 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000586-45/BE).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudract 2014-000586-45Funding StatementFunding This research was supported by the Branco Weiss fellowship of the Society in Science - ETH Zurich and by grants from the Flanders Fund for Scientific Research (FWO projects KAN 1506716N, KAN 1521313N, G040112 & G079017N). S.B. is supported by a fund of the Marguerite-Marie Delacroix foundation. Authors’ contributions SB acquired, prepared and analysed the data, and drafted and revised the manuscript. KA and JS designed the study and revised the manuscript. KA also analysed the data. GB and BB provided intellectual contribution to the manuscript and revised the manuscript. All authors read and approved the final manuscript. Acknowledgements We are thankful to all the participating subjects and all the master students who helped with the data collection. We specifically want to acknowledge Claudia Dillen for her help during the start of the clinical trial. We also thank our colleagues of the Leuven Autism Research Consortium. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request.OToxytocinASDautism spectrum disorderDSMDiagnostic and Statistical Manual of Mental DisordersADOSAutism Diagnostic Observation ScheduleIUinternational unitsMRImagnetic resonance imagingPLplaceboPOMSProfile of Mood StatesSRS-ASocial Responsiveness ScaleRBS-RRepetitive Behavior Scale – RevisedSAAMState Adult Attachment MeasureIPPAInventory of Parent and Peer AttachmentWHO-QOLWorld Health Organization Quality of Life